Abstract 237P
Background
The purpose of this paper is to report the dosimetric effects of conscious sparing of contralateral lobe of thyroid gland in select head and neck patients receiving intensity-modulated radiotherapy to ipsilateral neck only. In unilaterally treated neck, the thyroid lobe present contralaterally is passively spared. We compared the effects of consciously sparing it and associated dosimetric results and their statistical significance.
Methods
Treatment plans of 38 buccal mucosa cancer patients, treated to ipsilateral side only, receiving same dose and fractionation to buccal mucosa & elective neck irradiation were evaluated. Since October 2021 we adopted a department protocol of conscious sparing of contralateral thyroid in unilaterally treated head and neck cancer patients. 19 of these had conscious sparing of contralateral thyroid (group A) whereas 19 of old plans were evaluated when C/L thyroid were not given constraints & are being passively spared due to location on contralateral/non treatment side of neck (group B). Treatment planning was done using 7 beam (6 MV) IMRT in Eclipse 13.7 TPS in all of these patients. The best treatment plans were selected ensuring 95% PTV dose coverage and acceptable dose to organs at risk (OARs). Uniform contouring, plan optimization and evaluation protocols were followed for all of these patients.
Results
The mean dose of thyroid in group A was 10.23Gy whereas in group B it was 19.35Gy which is statistically significant (P value – 0.0001). The mean thyroid volume in group A was 4.76cc and in group B was 5.86cc which is not significant statistically different from group B, thyroid dose. Table: 237P
Groups | No. | Mean ± SD | ‘t’ value | P value |
Thyroid dose with constraint | 19 | 10.23 ± 2.18 | 9.004, df=36 | 0.0001* |
Thyroid dose without constraint | 19 | 19.35 ± 3.84 |
Unpaired ‘t’ test applied. P value = 0.0001, Significant
Conclusions
Unilateral treatment of neck passively reduces dose to OARs present on the contralateral side. This study emphasizes that conscious sparing of contralateral thyroid lobe can further reduce the dose to significant levels. This reduction can preserve thyroid function further. Larger clinical trials are required to corroborate this dosimetric gain with clinical thyroid function preservation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
186P - Degradation of BRCA2 expression by hyperthermia sensitizes HRD-negative (BRCA2 wild-type) ovarian cancer cells to niraparib
Presenter: Junyang Li
Session: Poster viewing 03
187P - BUB1 (2530C>T) polymorphism and expression affects chemotherapy response and predicts poor prognosis in advanced epithelial ovarian cancer
Presenter: Sinjini Sarkar
Session: Poster viewing 03
188P - Spatial transcriptomic analysis of tumor tissue in ovarian cancer patients treated with neoadjuvant chemotherapy
Presenter: Irina Larionova
Session: Poster viewing 03
189P - LncRNA NKILA as a negative regulator of NFkB in ascites in ovarian cancer
Presenter: Dinara Dolgova
Session: Poster viewing 03
190P - Real-world applications of poly (ADP-ribose) polymerase inhibitors for ovarian cancer: A single-center study in China
Presenter: dengfeng wang
Session: Poster viewing 03
191P - Phase II study of sodium valproate in combination with oral etoposide in platinum-resistant ovarian cancer
Presenter: N Thejeswar
Session: Poster viewing 03
192P - Human epididymis protein 4 as a predictor of response to neoadjuvant chemotherapy in epithelial ovarian cancer
Presenter: Sarada Planjery
Session: Poster viewing 03
193P - Experience with olaparib in the treatment of BRCA-associated tumors in real clinical practice: Experience of re-challenge mode of olaparib usage
Presenter: Alexander Sultanbaev
Session: Poster viewing 03
194P - A study of the treatment response of concomitant external beam radiotherapy (EBRT) and intracavitary brachytherapy in the management of locally advanced carcinoma of uterine cervix
Presenter: Asish Chowdhury
Session: Poster viewing 03
195P - Awareness of human papillomavirus (HPV) infection, cervical cancer (CC), and vaccine among females in Sultanate of Oman
Presenter: Abdulrahman Al-Mirza
Session: Poster viewing 03